Solventum (SOLV) Stock Price, Fundamentals & Analysis

What SOLV does

Solventum (SOLV) is a healthcare company that develops, manufactures, and commercialises medical products and software solutions in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers products such as negative pressure wound therapy, advanced wound dressings, surgical supplies, and medical electrodes. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, and restorative cements. The Health Information Systems segment offers software solutions for physician documentation, coding automation, and data visualisation.

Key numbers explained

• Solventum trades at 88.37 USD, with a marketCap of 15.04B USD, placing it among large-cap stocks and part of the S&P 500.
• The trailing P/E ratio of 10.8 and forward P/E ratio of 12.2 show how the market values the company relative to its current and expected earnings.
• Earnings per share (trailing 12 months) is 8.17 USD, representing the portion of profit attributable to each share.
• The dividend yield is 0%, and 0% of earnings are paid out as dividends, meaning the company currently returns no cash to shareholders via dividends.
• Beta of 0.69 indicates the stock tends to be less volatile than the overall market.
• The 52-week price range is 62.38 – 94.16, with a 23.6% price change over the last year.
• Revenue (trailing 12 months) is 8.31B USD, growing 2.2% year over year, with a profitMargin of 17.3% and operatingMargin of 9.8%.
• Return on equity is 34%, reflecting strong profitability relative to shareholder capital, while the debt-to-equity ratio of 110.3% shows debt exceeds equity.

Recent news

Recent headlines highlight analyst views on holding Solventum stock, the impact of its earnings beat and surgical AI initiatives, and its post-earnings price movement. Coverage also includes broader pieces on mid-cap stocks and S&P 500 stocks with open questions, situating SOLV within the wider medical instruments landscape alongside peers such as Medtronic (MDT) and Boston Scientific (BSX).

What to watch

Investors tracking SOLV typically monitor earnings reports, product launches in wound care and surgical equipment, and regulatory developments in the medical devices sector. Broader factors include healthcare policy changes, currency movements affecting international sales, and competitive dynamics with companies like Baxter International (BAX) and West Pharmaceutical Services (WST). The next earnings release is scheduled for 5 nov. 2026.